(Symbolic Image). In Type 1 diabetes, the immune system destroys insulin-producing cells in the pancreas, forcing patients to receive insulin externally for life. A cell therapy developed in the lab aims to replace this lost function with a one-time infusion. Data presented in the New England Journal of Medicine suggests a potential turning point in treatment.
The lab-developed cell therapy named Zimislecel is administered to patients with particularly severe Type 1 diabetes as a single infusion via the portal vein, settling in the liver. About 0.8 billion cultured islet cells form functional cell clusters that autonomously register and respond to blood sugar levels. Researchers report a fundamental metabolic transformation in twelve treated individuals within a year, marking a potential turning point in regenerative medicine.
Understanding Type 1 Diabetes
Type 1 diabetes occurs when the immune system mistakenly attacks insulin-producing beta cells in the pancreatic islets, leading to their complete destruction. Without these cells, the body cannot independently regulate blood sugar, requiring patients to administer insulin externally, often through daily injections or a pump. While insulin therapy keeps metabolism alive, it does not perfectly replicate the delicate regulation of a healthy body.
Patients with severe hypoglycemia, particularly those who cannot sense these episodes, are at increased risk. Severe hypoglycemia can become life-threatening in a short time. Research has been ongoing for decades to find a solution that permanently restores pancreatic function, making daily monitoring unnecessary.
How Zimislecel Works
The Zimislecel therapy, developed by Vertex Pharmaceuticals from lab-cultivated stem cells, regenerates fully differentiated insulin-producing cells under controlled conditions. Administered as a one-time infusion, the cells establish themselves in the liver, forming functional tissue. Unlike traditional donor organ transplants, these cells can be produced virtually unlimited, circumventing the longstanding shortage of suitable donors.
This stem cell therapy is one of the most intensely observed areas in current diabetes research. To prevent rejection of the foreign cells, patients require accompanying immunosuppressive medication.
Function of Cultivated Islet Cells
After the infusion, transplanted islet cells measure blood sugar levels and release insulin as necessary, similar to a healthy pancreas. Researchers track C-peptide, a reliable marker for endogenous insulin production. A study published in The New England Journal of Medicine confirmed that all treated individuals exhibited glucose-dependent insulin secretion, stable throughout the year-long observation period.
Participants achieved the target values set by the American Diabetes Association, maintaining a long-term blood sugar level below seven percent and spending over seventy percent of their time within optimal blood sugar ranges.
Clinical Study Outcomes
Twelve adults with difficult-to-control Type 1 diabetes received approximately 0.8 billion cells as a single infusion and were observed for at least a year. Notably, all twelve individuals remained free from severe hypoglycemia after the ninetieth day and reduced their daily insulin needs by an average of ninety-two percent. Official data from Vertex Pharmaceuticals indicate that ten of the twelve patients required no additional insulin after twelve months, achieving complete insulin independence.
This development significantly alters daily life for those previously dealing with the most challenging form of the disease, alleviating the burdens of constant blood sugar monitoring and painful injections.
Limitations and Path to Approval
Despite impressive results, this treatment currently remains limited to the most severe cases. A major drawback includes the necessity of ongoing immunosuppression, which increases the risk of infections and long-term complications. The study noted a higher occurrence of reduced white blood cell counts and two reported fatalities, attributed to unrelated health issues.
The small participant size and short observation period further limit the findings. Several research groups are working toward eliminating the need for immunosuppressants, exploring options like genetically modified or encapsulated cells. A significant Phase 3 trial is underway, involving around fifty participants before applications for approval will be made to U.S. and European authorities.
The New England Journal of Medicine, Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes; doi:10.1056/NEJMoa2506549
